Otezla (Apremilast): The 2028 Generic Opportunity Window
Otezla, Amgen's oral PDE4-inhibitor pill for plaque psoriasis and psoriatic arthritis, generated nearly $2.3 billion in global sales in 2025, and no generic version is commercially sold in the United States today. Its core composition-of-matter patent, US 7,427,638, runs to February 16, 2028, supported by a 2023 Federal Circuit permanent injunction barring generic market entry. Multiple Indian generic manufacturers - including Zydus Lifesciences, Glenmark Pharmaceuticals, and Dr. Reddy's Laboratories - already hold tentative FDA approvals or settled ANDA filings, setting up an immediate generic transition upon patent expiration.
What we do
We track expirations like this continuously
This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.